Where did our name come from?

We’re called Q’Apel for the Qu’Appelle River, a waterway that winds through Saskatchewan, Canada. Why? Because this pristine river charts a winding path, full of twists, turns, and straightaways alike. That’s what we do, too. Our cutting-edge products—neurological catheters, specifically—are designed to navigate the twists and turns of the brain’s neurovasculature, empowering therapeutic thrombectomy and cerebral aneurysm devices to deliver life-changing outcomes.

Who We Are
View All Resources

Systematic evaluation of patients treated with neurothrombectomy devices for acute ischemic stroke.

October 1, 2017

Abstract, via the American Heart Association Journal:

Mechanical thrombectomy with stent retrievers has become standard of care for treatment of acute ischemic stroke patients because of large vessel occlusion.

The STRATIS registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) aimed to assess whether similar process timelines, technical, and functional outcomes could be achieved in a large real world cohort as in the randomized trials.

Publication Link:
https://www.ahajournals.org/

Related readings.

Our utmost commitment: creating what works based specifically and urgently on what’s needed. Explore additional resources, publications, and webinars to learn more.

October 31, 2024

Q’Apel Medical Appoints Jay Hallinan as Chief Commercial Officer

Read
July 22, 2024

Q’Apel Medical Announces Leadership Transition

Read
October 12, 2021

Q’Apel Medical, Inc. Awarded U.S. Patent for its Highly Innovative SelectFlex™ Technology

Read
August 23, 2021

Q’Apel Medical Launches Armadillo – A New Radial Artery Access Platform to Meet the Needs of Physicians and Patients

Read